Structural evolution progress of orally bioavailable selective estrogen receptor degraders

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Estrogen receptor alpha (ERα) is a key target in breast cancer endocrine therapy.
• Fulvestrant, an intramuscular selective estrogen receptor degrader (SERD), effectively reduces ER levels but has clinical limitations.
• The need for orally bioavailable SERDs is critical for improved patient outcomes.

Purpose of the Study:

• To review recent advancements in oral selective estrogen receptor degraders (SERDs).
• To discuss the evolutionary relationships and structural modifications of oral SERDs.
• To provide insights for future research and clinical applications of oral SERDs.

Main Methods:

• Literature review of recent advancements in oral SERDs.
• Analysis of SERD efficacy, binding capacity, and safety profiles.
• Examination of structural modification processes for oral SERDs.

Main Results:

• Several oral SERDs have been developed and evaluated for efficacy and safety.
• Understanding of ER degradation mechanisms and binding capacities has advanced.
• Structural modifications are key to achieving oral bioavailability and desired therapeutic effects.

Conclusions:

• Oral SERDs represent a significant advancement over intramuscular formulations like Fulvestrant.
• Continued research into structural modifications and clinical evaluation is essential for optimizing oral SERD therapy.
• Oral SERDs hold substantial promise for improving breast cancer treatment strategies.